Self-Replicating mRNA Hits America, Cardiac Arrests Skyrocket
Please enjoy this quick-hitting update on Worldview Tube hosted by Brannon Howse.
He led the program with news that Arcturus Therapeutics has received FDA clearance to proceed with a clinical trial for ARCT-2304, a self-amplifying mRNA vaccine candidate targeting H5N1 pandemic influenza.
The Phase 1 clinical trial, funded by the National Institutes of Health (BARDA), will evaluate safety, reactogenicity, and immunogenicity in approximately 200 healthy adults in the United States.
The vaccine utilizes Arcturus’ STARR® self-amplifying mRNA technology and is part of the company’s preparation efforts for potential future pandemics.
Neither Arcturus nor BARDA has disclosed what will turn off self-replication or how this new technology will safely stop producing the potentially deadly H5N1 hemagglutinase Spike protein.

We covered the recent peer-reviewed report of skyrocketing cardiac arrests in Seattle after 98% of the population took the COVID-19 vaccine.
Finally, we spent time on the tremendous impact the nomination of Robert F. Kennedy, Jr for Secretary of Health and Human Services is having on the Bio-Pharmaceutical Complex.

Watch here :
See more here Substack
Please Donate Below To Support Our Ongoing Work To Defend The Scientific Method
PRINCIPIA SCIENTIFIC INTERNATIONAL, legally registered in the UK as a company incorporated for charitable purposes. Head Office: 27 Old Gloucester Street, London WC1N 3AX.
Trackback from your site.